Exact Sciences Corp at Raymond James Institutional Investors Conference Transcript
Good afternoon, everybody. Thanks for joining us. I'm Andrew Cooper, the diagnostics analyst here at Raymond James. We're happy to have Exact Sciences here. We've got Jeff Elliott, CFO; we've got Megan in IR in the back as well. I'm going to hand it over to Jeff to give us a quick overview here, and then we'll jump into fireside chat in just a few minutes. So Jeff?
Thanks, Andrew, and thanks to all of you. It's great to be back in front of an audience in-person presenting again. Hopefully, we can keep you on this going forward.
So we are Exact scientists. We are a leading global advanced cancer diagnostics company. Today, we have about 7,000 employees around the globe. This year, we expect to do about $2 billion of revenue. Our leading products are Cologuard, which is a noninvasive test for colorectal cancer; also Oncotype, which is the primary test there is a test for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
